Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1

Eliglustat is an oral glucosylceramide synthase inhibitor indicated for the long-term treatment of adults with Gaucher disease type 1 and CYP2D6 extensive, intermediate, or poor metabolizer phenotypes. Eliglustat is metabolized primarily by CYP2D6 and to a lesser extent by CYP3A4 and is a substrate...

Descripción completa

Detalles Bibliográficos
Autores principales: Vu, Lucie, Cox, Gerald F., Ibrahim, Jennifer, Peterschmitt, M. Judith, Ross, Leorah, Thibault, Nathan, Turpault, Sandrine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976987/
https://www.ncbi.nlm.nih.gov/pubmed/31993325
http://dx.doi.org/10.1016/j.ymgmr.2019.100552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976987/
https://www.ncbi.nlm.nih.gov/pubmed/31993325
http://dx.doi.org/10.1016/j.ymgmr.2019.100552

Ejemplares similares